Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity
- 1 December 2020
- journal article
- research article
- Published by Wiley in Acta Ophthalmologica
- Vol. 98 (8), E1004-E1008
- https://doi.org/10.1111/aos.14460
Abstract
Purpose To compare the effectiveness of intravitreal conbercept and ranibizumab treatment for retinopathy of prematurity (ROP). Methods In this retrospective study, the date of patients with ROP treated with intravitreal conbercept or ranibizumab from July 2012 to March 2018 with at least 12 months of follow-up at the Eye Center in People's Hospital of Peking University were analysed. Regression, progression or recurrence and peripheral retina vascularization were evaluated. Results In total, 283 eyes (145 infants) with conbercept treatment and 916 eyes (480 infants) with ranibizumab treatment were enrolled. In zone I ROP and aggressive posterior ROP (APROP), the recurrence prevalence was 49.09% (108/220 eyes) and 28.57% (10/33 eyes), and the recurrence interval was 7.87 +/- 0.65 (5.5-9.5) weeks and 10.6 +/- 1.53 (10.5-13) weeks in the ranibizumab and conbercept groups, respectively. In zone II ROP disease, the recurrence prevalence was 23.56% (164/696 eyes) and 13.31% (33/248 eyes), and the interval of recurrence was 8.40 +/- 0.88 (6-10.5) weeks and 11.4 +/- 1.35 (11-13.5) weeks in the ranibizumab and conbercept groups, respectively. The recurrence prevalence was significantly higher with ranibizumab in Zone I ROP and APROP (p = 0.006) and Zone II ROP (p < 0.001), and the recurrence interval was significantly longer in the conbercept group than that in the ranibizumab (p < 0.001). There was no significant difference in the rate of retinal vascularization (p = 0.441). Conclusion Conbercept and ranibizumab are effective for treating ROP. Compared with ranibizumab, conbercept resulted in less recurrence and longer treatment intervals.This publication has 22 references indexed in Scilit:
- Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbitExperimental Eye Research, 2012
- The discovery of placenta growth factor and its biological activityExperimental & Molecular Medicine, 2012
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityThe New England Journal of Medicine, 2011
- Long-term visual outcomes of laser-treated threshold retinopathy of prematurity: a study of refractive status at 7 yearsEye, 2009
- Through The Eyes of a Child: Understanding Retinopathy through ROP The Friedenwald LectureInvestigative Ophthalmology & Visual Science, 2008
- The Pharmacology Study of a New Recombinant Human VEGF Receptor-Fc Fusion Protein on Experimental Choroidal NeovascularizationPharmaceutical Research, 2008
- Potential Role of Microglia in Retinal Blood Vessel FormationInvestigative Ophthalmology & Visual Science, 2006
- New roles for VEGF in nervous tissue?beyond blood vesselsExperimental Neurology, 2004
- Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implicationsSeminars in Oncology, 2002
- Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature miceNature Medicine, 2002